We are live on !
Find out more
Column Group Portfolio holdings
AUM
$88.1M
Turnover
0%
1-Year Est. Return
148.03%
This Fund
S&P 500
This Quarter Est. Return
+24.4%
1 Year Est. Return
+148.03%
3 Year Est. Return
+95.12%
5 Year Est. Return
+23.89%
10 Year Est. Return
–
AUM
$82.8M
AUM Growth
+$1.83M
(+2.3%)
Cap. Flow
+$5.38M
Cap. Flow % of AUM
Cap. Flow %
6.5%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
1
Reduced
1
Closed
–
Avg Time Held
4.7
years
Top 10 Avg Time Held
4.7
years
Top 20 Avg Time Held
4.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Surrozen
SRZN
|
+$5.69M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
RAPT Therapeutics
RAPT
|
+$304K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Surrozen
SRZN
$384M
| $41.8M | 50.54% |
1,851,350
+351,577
| +23% | +$5.69M |
2021 Q3
17 quarters
|
|
2
Oric Pharmaceuticals
ORIC
$924M
| $29M | 34.98% |
3,540,777
| – | – |
2020 Q4
20 quarters
|
|
3
Tenaya Therapeutics
TNYA
$84.5M
| $6.69M | 8.08% |
9,400,290
| – | – |
2021 Q3
17 quarters
|
|
|
4
DELISTED
RAPT Therapeutics
RAPT
| $5.29M | 6.39% |
156,270
-9,805
| -6% | -$304K |
2020 Q4
20 quarters
|
|
5
Revolution Medicines
RVMD
$41.8B
| $3.66K | ﹤0.01% |
46
| – | – |
2020 Q4
20 quarters
|
|
Similar funds
KFP
Column Group's Q4 2025 Portfolio in Review
As of Q4 2025, Column Group held 5 positions worth $82.8M, up 2.3% from $81M the previous quarter. Its ten largest holdings account for 100% of the portfolio.
Column Group deployed $5.38M of net new capital in Q4 2025, adding to 1 existing holding.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was RAPT Therapeutics, an estimated $304K trimmed.
- Column Group added most to Surrozen in Q4 2025, an estimated $5.69M increase.
- Column Group's biggest Q4 2025 reduction was RAPT Therapeutics, cutting an estimated $304K.
- Column Group's ten largest holdings make up 100% of its $82.8M portfolio in Q4 2025.
- Column Group opened 0 new positions and closed 0 in Q4 2025.
- Column Group's portfolio value rose 2.3% quarter-over-quarter to $82.8M.
Based on Column Group's 13F filing for Q4 2025, filed 13 Feb 2026.